| Type |
Comments |
References |
|
Cells
|
|
|
| CD3+CD4+CD69+ T cells |
Independent prognostic factor for overall survival |
59
|
| CD19+ B lymphocytes |
High levels found in patients with advanced stage |
31
|
| Peripheral NK cells |
Increased in metastatic melanoma |
69,70
|
| Circulating monocytic (Mo)-MDSCs |
Correlated with disease progression |
6
|
|
Molecules
|
|
|
| LDH |
Staging and prognosis marker |
76
|
| S100B, MIA |
Common used markers for prognosis and monitoring therapy |
80
|
| Serum amyloid A, C reactive protein |
Acute phase reactant protein |
84
|
| Ceruloplasmin |
Acute phase reactant protein |
85
|
| TNFR2, TGF-alpha, TIMP1, CRP |
Mediators of chronic inflammatory, indicators of immunosuppressive status |
86
|
| TNF-alpha, soluble interleukin-2 receptor and beta-2 microglobulin |
Predictive markers of relapse |
87
|
| IL-6, IL-8, TNF-alpha |
Cytokines, staging markers |
31
|
| IL1-beta |
Marker of metastasis |
31
|
| TGF-beta1 |
Growth factor involved in skin inflammation, marker for diagnosis and prognosis |
97
|
| Cytokines IL-4, IL-10, Il-13 and chemokines CCL5(RANTES), CXCL10 |
High levels of Th2 cytokines in patient plasma with metastatic melanoma |
61-63
|
